EcoDrugPlus

24-Dehydrocholesterol Reductase

Ensembl ID : ENSXETG00000020010
Gene Symbol: DHCR24
6 Enzyme and pathways 5 View Cross-references
208 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

3-Hydroxy-3-Methylglutaryl-Coa Reductase

Ensembl ID : ENSXETG00000005084
Gene Symbol: HMGCR
4 Enzyme and pathways 5 View Cross-references
270 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

3-Phosphoinositide Dependent Protein Kinase 1

Ensembl ID : ENSXETG00000004025
Gene Symbol: PDPK1
40 Enzyme and pathways 5 View Cross-references
243 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

4-Hydroxyphenylpyruvate Dioxygenase

Ensembl ID : ENSXETG00000003766
Gene Symbol: HPD
5 View Cross-references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5'-3' Exoribonuclease 1

Ensembl ID : ENSXETG00000046350
Gene Symbol: ATR
6 Enzyme and pathways 5 View Cross-references
206 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5'-Nucleotidase, Ecto (Cd73)

Ensembl ID : ENSXETG00000018096
Gene Symbol: NT5E
8 Enzyme and pathways 5 View Cross-references
250 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine (Serotonin) Receptor 1b, G Protein-Coupled

Ensembl ID : ENSXETG00000011743
Gene Symbol: HTR1B
5 View Cross-references
245 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine (Serotonin) Receptor 1d, G Protein-Coupled

Ensembl ID : ENSXETG00000047747
Gene Symbol: HTR1D
8 Enzyme and pathways 5 View Cross-references
67 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine (Serotonin) Receptor 1e, G Protein-Coupled

Ensembl ID : ENSXETG00000038202
Gene Symbol: HTR1E
8 Enzyme and pathways 5 View Cross-references
155 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine (Serotonin) Receptor 1f, G Protein-Coupled

Ensembl ID : ENSXETG00000048103
Gene Symbol: HTR1F
8 Enzyme and pathways 5 View Cross-references
145 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine (Serotonin) Receptor 2a, G Protein-Coupled

Ensembl ID : ENSXETG00000032623
Gene Symbol: HTR2A
8 Enzyme and pathways 5 View Cross-references
219 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

5-Hydroxytryptamine (Serotonin) Receptor 2b, G Protein-Coupled

Ensembl ID : ENSXETG00000009523
Gene Symbol: HTR2B
8 Enzyme and pathways 5 View Cross-references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).